Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older at the time of signing the consent form
- People who have been diagnosed with a type of breast cancer called adenocarcinoma, where the cancer has come back or spread to other parts of the body and cannot be cured
- People whose cancer continued to grow during or after at least two previous hormone-based treatments for recurrent or metastatic disease (if the cancer came back during or within six months of stopping a hormone treatment taken after surgery, that treatment counts as one of the two)
- People who have previously been treated with a CDK4/6 inhibitor drug combined with a hormone-based therapy for recurrent or metastatic disease
- People whose cancer has been confirmed by a local laboratory to be hormone receptor-positive (HR+) and HER2-negative, tested according to recognised international guidelines
Who may not be able to join:
- People who have received chemotherapy for their recurrent or metastatic breast cancer
- People who have previously been treated with any drug that specifically targets a protein called Aurora Kinase A (AURKA), including a drug called alisertib, at any point in their cancer treatment
Important: There are additional criteria not listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chief Reg Affairs, PV, Medical Affairs and Law Officer, Puma Biotechnology, Inc.
Phone: 424-248-6500
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR) Within Dose Subgroup; Duration of Response (DOR) Within Dose Subgroup; Disease Control Rate (DCR) Within Dose Subgroup; Progression Free Survival (PFS) Within Dose Subgroup; Overall Survival (OS) Within Dose Subgroup; Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.